Literature DB >> 11342466

Induction of tolerance to human factor VIII in mice.

H Chao1, C E Walsh.   

Abstract

This paper reports loss of human factor VIII (hFVIII) inhibitory antibody in immunocompetent C57BL/6 mice. High-titer anti-hFVIII antibody developed in the mice within 7 to 14 days of intraportal administration of adeno-associated virus (AAV) carrying FVIII that coincided with a reduction in plasma hFVIII antigen. Bethesda titers (> 100 units) persisted relatively unchanged for 9 to 10 months. Unexpectedly, at 10 months after injection of the virus, hFVIII protein (up to 59 ng/mL) was detected in 3 mice at the same time as disappearance of hFVIII inhibitor. The level of hFVIII was similar to that found in immunodeficient mice receiving the same dose of recombinant AAV carrying hFVIII without hFVIII inhibitor. These results suggest that tolerance to hFVIII can be induced by sustained expression of hFVIII in a mouse model. Further elucidation of this observation may affect use of FVIII gene transfer in the treatment of inhibitor-positive patients with hemophilia A.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342466     DOI: 10.1182/blood.v97.10.3311

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Adenoassociated virus vectors for genetic immunization.

Authors:  Selvarangan Ponnazhagan
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Tolerance induction by viral in vivo gene transfer.

Authors:  Eric Dobrzynski; Roland W Herzog
Journal:  Clin Med Res       Date:  2005-11

3.  Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII.

Authors:  Chuhong Hu; Racel G Cela; Masataka Suzuki; Brendan Lee; Gerald S Lipshutz
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-18       Impact factor: 11.205

4.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

Authors:  Federico Mingozzi; Yi-Lin Liu; Eric Dobrzynski; Antje Kaufhold; Jian Hua Liu; YuQin Wang; Valder R Arruda; Katherine A High; Roland W Herzog
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

5.  A nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculation.

Authors:  Gene A Palmer; Jennifer L Brogdon; Stephanie L Constant; Peter Tattersall
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

6.  Enhanced factor VIII heavy chain for gene therapy of hemophilia A.

Authors:  Lingxia Chen; Hui Lu; Jinhui Wang; Rita Sarkar; Xiao Yang; Hongli Wang; Katherine A High; Weidong Xiao
Journal:  Mol Ther       Date:  2009-01-06       Impact factor: 11.454

7.  Engineering Factor Viii for Hemophilia Gene Therapy.

Authors:  Sean A Roberts; Biao Dong; Jenni A Firrman; Andrea R Moore; Nianli Sang; Weidong Xiao
Journal:  J Genet Syndr Gene Ther       Date:  2011-12-21

8.  Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I.

Authors:  Mark J Osborn; Ron T McElmurry; Christopher J Lees; Anthony P DeFeo; Zhi-Ying Chen; Mark A Kay; Luigi Naldini; Gordon Freeman; Jakub Tolar; Bruce R Blazar
Journal:  Mol Ther       Date:  2010-11-16       Impact factor: 11.454

9.  Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice.

Authors:  Taran S Lundgren; Gabriela Denning; Sean R Stowell; H Trent Spencer; Christopher B Doering
Journal:  Blood Adv       Date:  2022-04-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.